Download PDF
Semin Liver Dis 2004; 24: 63-70
DOI: 10.1055/s-2004-828680
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

HBV Infection in Patients With End-Stage Renal Disease

Fabrizio Fabrizi1 , 2 , Suphamai Bunnapradist1 , Paul Martin1
  • 1Center for Liver and Kidney Diseases and Transplantation, Cedars-Sinai Medical Center and Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, California
  • 2Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS, Milan, Italy
Further Information

Publication History

Publication Date:
11 June 2004 (online)

    Permissions and Reprints

Controlling the spread of hepatitis B virus (HBV) infection in dialysis units has been one of major triumphs in the management of end-stage renal disease. However, HBV incidence and prevalence rates remain high in dialysis patients in less-developed countries, and HBV within dialysis units continues to spread in the industrialized world. Overall response rates to HBV vaccination are lower in dialysis patients than in the nondialysis population. Lamivudine is effective in the treatment of HBV infection in the dialysis setting. Presence of hepatitis B surface antigen (HbsAg) has a negative impact on patient survival after renal transplantation. Several issues remain unanswered with regard to the management of HBV infection in dialysis patients, including the management of lamivudine resistance and the optimal timing and duration of antiviral therapy. Liver biopsy prior to renal transplantation is crucial in order to identify and exclude patients with advanced fibrosis or even cirrhosis.

KEYWORDS

Hepatitis B virus - renal disease - therapy - lamivudine

REFERENCES

  • 1 Snydman D R, Bryan J A, Hanson B. Hemodialysis-associated hepatitis in the United States-1972.  J Infect Dis. 1975;  132 109-113
    PubMedGoogle Scholar
  • 2 Centers for Disease Control and Prevention .Control Measures for Hepatitis Type B in Dialysis Centers. Viral Hepatitis Investigations and Control Series 1977
    Google Scholar
  • 3 Alter M J, Favero M S, Maynard J E. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States.  J Infect Dis. 1986;  153 1149-1151
    PubMedGoogle Scholar
  • 4 Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings.  MMWR Morb Mortal Wkly Rep. 1988;  37 377-382
    PubMedGoogle Scholar
  • 5 Kellerman S, Alter M J. Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics.  Hepatology. 1999;  29 291-293
    CrossrefPubMedGoogle Scholar
  • 6 Tokars J I, Frank M, Alter M J, Arduino M J. National surveillance of dialysis-associated diseases in the United States, 2000.  Semin Dial. 2002;  15 162-171
    CrossrefPubMedGoogle Scholar
  • 7 Burdick R A, Bragg-Gresham J L, Woods J D et al.. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.  Kidney Int. 2003;  63 2222-2229
    CrossrefPubMedGoogle Scholar
  • 8 Centers for Disease Control and Prevention . Outbreaks of hepatitis B virus infection among hemodialysis patients-California, Nebraska, and Texas, 1994.  JAMA. 1996;  275 1394-1395
    CrossrefPubMedGoogle Scholar
  • 9 Hutin Y J, Goldstein S T, Varma J K et al.. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis.  Infect Control Hosp Epidemiol. 1999;  20 731-735
    PubMedGoogle Scholar
  • 10 Fabrizi F, Lunghi G, Finazzi S et al.. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.  Am J Kidney Dis. 2001;  38 1009-1015
    PubMedGoogle Scholar
  • 11 Fabrizi F, Mangano S, Alongi G et al.. Influence of hepatitis B virus viremia upon serum aminotransferase activity in dialysis population.  Int J Artif Organs. 2003;  26 1048-1055
    PubMedGoogle Scholar
  • 12 Locatelli F, Marcelli D, Conte F et al.. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto.  Nephrol Dial Transplant. 2000;  15(Suppl 5) 69-80
    PubMedGoogle Scholar
  • 13 Maisonneuve P, Agodoa L, Gellert R et al.. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.  Lancet. 1999;  354 93-99
    CrossrefPubMedGoogle Scholar
  • 14 Josselson J, Kyser B A, Weir M R, Sadler J H. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality.  Am J Kidney Dis. 1987;  9 456-461
    PubMedGoogle Scholar
  • 15 Marcelli D, Stannard D, Conte F et al.. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States.  Kidney Int. 1996;  50 1013-1018
    PubMedGoogle Scholar
  • 16 Fabrizi F, Martin P. Hepatitis B vaccine and dialysis: current issues.  Int J Artif Organs. 2001;  24 683-694
    PubMedGoogle Scholar
  • 17 Rangel M C, Coronado V G, Euler G L, Strikas R A. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics.  Semin Dial. 2000;  13 101-107
    CrossrefPubMedGoogle Scholar
  • 18 Miller E R, Alter M J, Tokars J I. Protective effect of hepatitis B vaccine in chronic hemodialysis patients.  Am J Kidney Dis. 1999;  33 356-360
    PubMedGoogle Scholar
  • 19 Oddone E Z, Cowper P A, Hamilton J D, Feussner J R. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.  Health Serv Res. 1993;  28 97-121
    PubMedGoogle Scholar
  • 20 Duarte R, Huraib S, Said R et al.. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis.  Am J Kidney Dis. 1995;  25 40-45
    PubMedGoogle Scholar
  • 21 Rodrigues A, Morgado T, Areias J et al.. Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C.  Transplant Proc. 1997;  29 777-780
    CrossrefPubMedGoogle Scholar
  • 22 Fabrizi F, Lunghi G, Martin P. Recent advances in the management of hepatitis C in the dialysis population.  Int J Artif Organs. 2002;  25 503-511
    PubMedGoogle Scholar
  • 23 Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.  Am J Gastroenterol. 2000;  95 3579-3583
    CrossrefPubMedGoogle Scholar
  • 24 Boyacioglu S, Gur G, Gursoy M, Ozdemir N. Lamivudine in renal transplant candidates with chronic hepatitis B infection.  Transplant Proc. 2002;  34 2131-2132
    CrossrefPubMedGoogle Scholar
  • 25 Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection.  J Clin Gastroenterol. 2003;  37 64-67
    CrossrefPubMedGoogle Scholar
  • 26 Fontaine H, Thiers V, Chretien Y et al.. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients.  Transplantation. 2000;  69 2090-2094
    PubMedGoogle Scholar
  • 27 Fabrizi F, Martin P, Ponticelli C. Hepatitis B virus and renal transplantation.  Nephron. 2002;  90 241-251
    CrossrefPubMedGoogle Scholar
  • 28 Hiesse C, Buffer C, Neyrat N et al.. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation.  Clin Transplant. 1992;  6 461-467
    PubMedGoogle Scholar
  • 29 Mathurin P, Mouquet C, Poynard T et al.. Impact of hepatitis B and C virus on kidney transplantation outcome.  Hepatology. 1999;  29 257-263
    CrossrefPubMedGoogle Scholar
  • 30 Farza H, Salmon A M, Hadchouel M et al.. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice.  Proc Natl Acad Sci USA. 1987;  84 1187-1191
    PubMedGoogle Scholar
  • 31 Tur-Kaspa R, Burk R D, Shaul Y, Shafritz D A. Hepatitis B virus DNA contains a glucocorticoid-responsive element.  Proc Natl Acad Sci USA. 1986;  83 1627-1631
    CrossrefPubMedGoogle Scholar
  • 32 McMillan J S, Shaw T, Angus P W, Locarnini S A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro.  Hepatology. 1995;  22 36-43
    CrossrefPubMedGoogle Scholar
  • 33 Cote C, Tennant B, Baldwin B, Korba B, Gerin J. Modulation of WHV Infection and Disease with Cyclosporine A and Dexamethasone. International Symposium on Viral Hepatitis and Liver Disease 1990
    Google Scholar
  • 34 Fornairon S, Pol S, Legendre C et al.. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection.  Transplantation. 1996;  62 297-299
    CrossrefPubMedGoogle Scholar
  • 35 Rao K V, Kasiske B L, Anderson W R. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients.  Transplantation. 1991;  51 391-396
    PubMedGoogle Scholar
  • 36 Parfrey P S, Forbes R D, Hutchinson T A et al.. The impact of renal transplantation on the course of hepatitis B liver disease.  Transplantation. 1985;  39 610-615
    PubMedGoogle Scholar
  • 37 Grotz W, Gondolf K, Rasenack J et al.. Imminent liver failure in a hepatitis-B-positive renal-allograft recipient: successful therapy with interferon-alpha.  Nephrol Dial Transplant. 1995;  10 1932-1934
    PubMedGoogle Scholar
  • 38 Post A B, Hricik D E, Sterling R K et al.. Resolution of hepatitis B viremia in a renal transplant recipient treated with alpha-2b interferon.  Nephron. 1998;  79 469-471
    CrossrefPubMedGoogle Scholar
  • 39 Kramer P, ten Kate F W, Bijnen A B, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients.  Lancet. 1984;  1 989-990
    PubMedGoogle Scholar
  • 40 Rostaing L, Modesto A, Baron E et al.. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C.  Nephron. 1996;  74 512-516
    PubMedGoogle Scholar
  • 41 Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of HBV-related liver disease after renal transplantation: meta-analysis of clinical trials.  Transplantation. 2004;  77 859-864
    PubMedGoogle Scholar
  • 42 Perrillo R P. Hepatitis B and renal transplantation: securing the sword of Damocles.  Hepatology. 2002;  36 1041-1045
    CrossrefPubMedGoogle Scholar
  • 43 Fabrizi F, Lunghi G, Poordad F F, Martin P. Management of hepatitis B after renal transplantation: an update.  J Nephrol. 2002;  15 113-122
    PubMedGoogle Scholar
  • 44 Chan T M, Fang G X, Tang C S et al.. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.  Hepatology. 2002;  36 1246-1252
    CrossrefPubMedGoogle Scholar
  • 45 Schwarz A, Krause P H, Offermann G, Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation.  Transplantation. 1994;  58 650-654
    PubMedGoogle Scholar
  • 46 Rostaing L, Henry S, Cisterne J M et al.. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation.  Transplantation. 1997;  64 1624-1627
    PubMedGoogle Scholar
  • 47 Goffin E, Horsmans Y, Squifflet J P et al.. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients.  Transplantation. 1999;  12 322-327
    PubMedGoogle Scholar
  • 48 Hung Y O, Lee Y, Yang W S et al.. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients.  Transplantation. 1998;  66 733-737
    PubMedGoogle Scholar
  • 49 Kletzmayr J, Watschinger B, Muller C et al.. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients.  Transplantation. 2000;  70 1404-1407
    PubMedGoogle Scholar
  • 50 Tsai M K, Lai M Y, Hu R H et al.. Managing hepatitis B reactivation in renal transplant recipients: A 12-year review with emphasis on early detection and early use of lamivudine.  Transplant Proc. 2000;  32 1935-1936
    CrossrefPubMedGoogle Scholar
  • 51 Lewandowska D, Durlik M, Kukula K et al.. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients.  Transplant Proc. 2000;  32 1369-1370
    CrossrefPubMedGoogle Scholar
  • 52 Antoine C, Landau A, Menoyo V et al.. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B.  Transplant Proc. 2000;  32 384-385
    CrossrefPubMedGoogle Scholar
  • 53 Mouquet C, Bernard B, Poynard T et al.. Chronic hepatitis B treatment with lamivudine in kidney transplant patients.  Transplant Proc. 2000;  32 2762
    CrossrefPubMedGoogle Scholar
  • 54 Lee W C, Wu M J, Cheng C H et al.. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.  Am J Kidney Dis. 2001;  38 1074-1081
    PubMedGoogle Scholar
  • 55 Han D J, Kim T H, Park S K et al.. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence.  Transplantation. 2001;  71 387-394
    PubMedGoogle Scholar
  • 56 Park S K, Yang W S, Lee Y S et al.. Outcome of renal transplantation in hepatitis B surface antigen-positive after introduction of lamivudine.  Nephrol Dial Transplant. 2002;  16 2222-2228
    PubMedGoogle Scholar
  • 57 Mosconi G, Scolari M P, Manna C et al.. Lamivudine in recurrent hepatitis B after renal transplantation.  Transplant Proc. 2001;  33 1873-1874
    CrossrefPubMedGoogle Scholar

Paul MartinM.D. 

Center for Liver and Kidney Diseases and Transplantation, Cedars-Sinai Medical Center

8635 W. Third St., Suite 590W, Los Angeles, CA 90048

Email: martinpx@cshs.org

      >